US FDA misses approval deadline for Amgen's Nplate
This article was originally published in Scrip
Executive Summary
The US FDAhas missed the user fee date for regulatory action on Amgen's platelet-boosting agent Nplate (romiplostim). The company said it was notified by the agency that a decision would not be issued by the July 23rd deadline.